A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Clinical trial NCT03430843 · COMPLETED
Trial details
- NCT number
- NCT03430843
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-26
- Primary completion
- 2020-12-01
- Enrollment
- 512
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.